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1  | INTRODUC TION
The hepatitis B virus (HBV) is a non- cytopathic DNA virus that in-
fects hepatocytes and frequently causes a lifelong infection. As 
such, it accounts for up to 780 000 deaths annually. Nucleos(t)ide 
analogues (NA) efficiently suppress viral replication and substan-
tially improve survival of chronic HBV patients. However, loss of 
the hepatitis B surface antigen (HBsAg) is rare in patients under NA 
treatment, often requiring years to decades.1
Over the last years, the feasibility of stopping NA treatment prior 
to HBsAg loss has been extensively investigated in long- term virally 
suppressed hepatitis B e antigen (HBeAg)- negative hepatitis B pa-
tients.2 Although viral relapse was found to be frequent, subsequent 
HBsAg loss has been reported in up to 39% of the patients.3 This has 
been ascribed to beneficial alanine aminotransferase (ALT) flares with 
concomitantly restored HBV- specific T- cell responses.4,5 However, in 
a recent, large cohort study of 691 HBeAg- negative hepatitis patients, 
sustained viral suppression rather than any type of relapse following 
treatment withdrawal was associated with HBsAg seroclearance.6
Abbreviations: ALT, Alanine aminotransferase; Anti-HBe, Anti-hepatitis B e antigen anti-
body; Anti-HBs, Anti-hepatitis B surface antigen antibody; AST, Aspartate aminotransfer-
ase; Gamma-GT, Gamma-glutamyl transferase; HBeAg, Hepatitis B e antigen; HBsAg, 
Hepatitis B surface antigen; HBV, Hepatitis B virus; IQR, Interquartile range; NA, 
Nucleos(t)ide analogues; SD, Standard deviation; ULN, Upper limit of normal.
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HBsAg loss following NA withdrawal in HBeAg- positive hepatitis 
patients with NA- induced HBeAg seroconversion has been less well 
studied. These data are relatively difficult to obtain, given the low 
prevalence of these patients and the common practice of continuing 
treatment until HBsAg loss in many countries.7 In the current study, 
we examine HBsAg loss following treatment cessation in an inter-
national, multi- ethnic cohort of patients with recent NA- induced 
HBeAg seroconversion.
2  | METHODS
2.1 | Patients
This retrospective, observational cohort study included all con-
secutive NA- treated chronic hepatitis B patients who experienced 
treatment- induced HBeAg seroconversion and subsequently 
stopped treatment between December 2000 and October 2016 
at 20 hospitals in Belgium, the Netherlands and Canada. Exclusion 
criteria were concomitant infection with the hepatitis C virus, hepa-
titis delta virus or human immunodeficiency virus, the use of long- 
term immunosuppressive medication (>2 weeks), peg- interferon 
add- on treatment and a lack of follow- up after treatment cessation. 
Outpatient visits with routine laboratory assessment were sched-
uled at least every 3- 6 months at all participating centres.
2.2 | Data collection
Data on demographics (date of birth, ethnicity and gender), virology 
(HBeAg status, HBsAg status, HBV viral load and HBV genotype), 
biochemistry (ALT, aspartate aminotransferase (AST), gamma- 
glutamyl transferase (gamma- GT)), treatment (type and duration) 
and the presence of cirrhosis were collected systematically accord-
ing to predefined criteria using the same case record form for all 
patients. The diagnosis of cirrhosis was made according to interna-
tional guidelines, via a combination of clinical, elastographical and 
imaging studies, or histologically. The limit of quantification for HBV 
DNA varied between 12 IU/mL and 2000 IU/mL, depending on the 
year of determination. HBV DNA levels below the limit of detec-
tion and below the limit of quantification were assigned the arbitrary 
values of 0 and the lower limit of quantification, respectively. HBV 
genotyping was performed using the INNO- LiPA test (Fujirebio, 
Ghent, Belgium).
2.3 | Definitions
HBeAg and HBsAg loss/seroconversion was defined as the loss of 
HBeAg and HBsAg respectively and the appearance of antibodies 
against HBeAg (anti- HBe) and HBsAg (anti- HBs) respectively on two 
occasions at least 1 month apart. HBeAg reversion was defined as 
the reappearance of HBeAg after confirmed HBeAg loss/serocon-
version. Sustained viral control was defined as continuous HBV DNA 
suppression <2000 IU/mL. Virologic relapse was defined as a sin-
gle HBV DNA elevation >2000 IU/mL after treatment cessation and 
clinical relapse as virologic relapse with ALT rise >2× upper limit of 
normal (ULN). The ULN for ALT was set at 40 IU/mL.
2.4 | Statistical analysis
Continuous data are shown as mean ± standard deviation (SD) or me-
dian (interquartile range (IQR)). Variables were compared between 
groups using a chi- square test for categorical variables and a Mann- 
Whitney U test, Student's t test or one- way analysis of variance 
(ANOVA) for continuous variables. Consolidation treatment dura-
tion was calculated as time from HBeAg seroconversion until treat-
ment cessation. A clock- reset approach was applied to investigate 
HBsAg loss rates according to the virologic outcome and retreat-
ment status after HBeAg seroconversion. Patients were considered 
as sustained viral controllers (n = 98) until relapse occurred (n = 62) 
with (n = 31) or without (n = 31) need for subsequent retreatment. 
Data were analysed with SPSS version 24.0 (IBM, Armonk, New 
York, USA). All statistical tests were two- sided, and P- values < 0.05 
were considered statistically significant.
3  | RESULTS
A total of 98 predominantly male (74.4%) patients of mixed ethnic-
ity (43.9% Asians, 49.0% Caucasians) who stopped treatment after 
NA- induced HBeAg seroconversion were included. Median consoli-
dation treatment duration was 11.4 (6.1- 18.0) months and median 
follow- up time after treatment cessation 42.8 (22.7- 83.2) months. 
An overview of the patient characteristics is depicted in Table S1.
Viral relapse (HBV DNA > 2000 IU/mL) was noted in 62 pa-
tients at a median of 6.1 (3.5- 16.7) months after treatment ces-
sation with concomitant ALT rise >2 × ULN in 30/62 and HBeAg 
reversion in 12/62. Retreatment was started in 31/62 relapsed 
patients, of whom 16 started retreatment immediately and 15 at 
a median of 3.1 (2.4- 15.2) months after relapse detection. HBsAg 
loss was observed in 14 patients off- treatment at a median of 
9.7 (5.3- 20.7) months after treatment cessation. Retreatment led 
to HBsAg loss in another 2 patients respectively 5.1 years and 
7.4 years after retreatment start with subsequent long- term viral 
suppression. Both patients showed an at onset severe clinical re-
lapse (HBV DNA 8.25 log IU/mL, ALT 4.35 ULN; and HBV DNA 
7.89 log IU/mL, ALT 10.63 ULN) for which immediate retreatment 
was deemed necessary.
Remarkably, all patients with off- treatment HBsAg loss showed 
persistently low ALT (<1.5 × ULN) and HBV DNA (<2000 IU/mL) lev-
els after HBeAg seroconversion (Figure 1). Using a clock- reset ap-
proach, annual HBsAg loss rates were examined according to the 
virologic outcome and retreatment status (Table S2). The annual 
HBsAg seroclearance rate was 8.4% in patients with off- treatment 
persistent viral control, compared to (a) 0.0% if relapse occurred but 
no retreatment was initiated (P = 0.009) and (b) 1.5% if relapse oc-
curred with subsequent retreatment (P = 0.008). Indeed, no HBsAg 
loss was observed in patients (n = 31) that showed a mild relapse 
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(peak median HBV DNA 4.02 log IU/mL; peak median ALT 0.9 ULN) 
but were not retreated during a median follow- up time of 1.9 (0.8- 
3.8) years after relapse detection. We next analysed whether base-
line parameters would be associated with off- treatment HBsAg loss 
(Table S3). Caucasian patients had significantly higher off- treatment 
annual HBsAg loss rates compared to non- Caucasian patients (7.2% 
vs 1.0%; P = 0.002; Table S3), while other baseline parameters were 
not significantly associated with HBsAg loss. Sustained viral sup-
pression resulted in annual HBsAg loss rates of 14.8% in Caucasian 
patients as opposed to 2.3% in non- Caucasian patients (P = 0.004; 
Table S4). Annual relapse rates tended to be lower in Caucasian pa-
tients (29.6% for Caucasian vs 44.2% for non- Caucasian patients; 
P = 0.052). With 48 Caucasian and 50 non- Caucasian patients, our 
cohort was well balanced for ethnicity.
4  | DISCUSSION
In the present study, we investigated off- treatment HBsAg loss in 
a multi- ethnic, international cohort of patients who stopped NA 
treatment following HBeAg seroconversion. We demonstrate that 
off- treatment HBsAg loss is exclusively seen in patients without viral 
relapse. In those that do relapse, HBsAg loss requires at least 5 years 
of viral suppression upon retreatment initiation.
These observations are in contrast with several small- scale 
NA stop studies in start- of- treatment HBeAg- negative patients, in 
which ALT flares after viral rebound have been found to facilitate 
HBsAg loss via a T- cell–dependent mechanism.4,5 Similar to our 
results however, most off- treatment HBsAg losses occurred in pa-
tients with sustained viral control in a large cohort of 691 Taiwanese 
start- of- treatment HBeAg- negative patients.6 These clinical obser-
vations raise questions on the concept of beneficial ALT flares and 
call for extensive translational studies in both HBeAg- positive and 
HBeAg- negative patients to unravel the immune responses that lead 
to off- treatment HBsAg loss.
Next to sustained viral control, we observed sevenfold higher 
annual HBsAg seroclearance rates in Caucasian patients compared 
to non- Caucasian patients. However, no other baseline character-
istics correlated with annual HBsAg loss rates, underlining the im-
portance of immune responses and possibly HBV genotypes in the 
observed HBsAg loss rates.8
Although this is to our knowledge the largest multi- ethnic 
study as of today assessing off- treatment HBsAg loss in pa-
tients with NA treatment–induced HBeAg seroconversion, the 
retrospective data collection might imply a variable number 
of laboratory values available per patient. Nevertheless, most 
patients were seen at the outpatient clinic every 3- 6 months, 
which is current real- life practice in large hepatitis centres. In 
addition, genotype testing and quantitative hepatitis B surface 
antigen levels were available in only a small proportion (n = 15 
and n = 14, respectively). Thus, we could not reliably evaluate 
the contribution of HBV genotypes or the diagnostic value of 
quantitative hepatitis B surface antigen levels for HBsAg loss. 
Second, despite pooling of all patients who stopped treatment 
at 20 centres across Belgium, the Netherlands and Canada, the 
number of patients that showed HBsAg loss after treatment 
cessation (n = 16) is limited and hampers multivariate statistical 
modelling approaches.
In conclusion, persistent viral control after treatment cessation 
following NA- induced HBeAg seroconversion was associated with 
high HBsAg loss rates in Caucasian patients. Our data raise ques-
tions on the concept of beneficial ALT flares and call for extensive 
translational studies into the immune mechanisms of off- treatment 
HBsAg loss.
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